BACKGROUND: Nevirapine is an important component of paediatric combination HIV therapy. Adequate drug exposure is necessary in order to achieve long-lasting viral suppression. OBJECTIVES: To study the influence of age, drug dose and formulation type, nutritional status and CYP2B6 516G>T polymorphism on blood concentrations of nevirapine in children treated with generic antiretroviral drugs. METHODS: A multicentre study was conducted at four sites in India. HIV-infected children receiving generic nevirapine-based fixed-dose combinations were recruited. Trough and 2 h nevirapine plasma concentrations were determined by HPLC. Characterization of the CYP2B6 gene polymorphism was performed using direct sequencing. Clinical and nutritional status was recorded. Groups were compared using the Mann-Whitney U-test and multivariable logistic regression analysis was performed to identify factors contributing to low drug levels. RESULTS: Ninety-four children of median age 78 months were studied; 60% were undernourished or stunted. Stunted children had a significantly lower 2 h nevirapine concentration compared with non-stunted children (P < 0.05); there were no significant differences in trough concentrations between different nutritional groups. Nevirapine levels were significantly higher in children with TT compared with GG and GT CYP2B6 genotypes (P < 0.01). Children ≤ 3 years had a 3.2 (95% confidence interval 1.07-9.45) times higher risk of having sub-therapeutic nevirapine concentrations. CONCLUSIONS: Nevirapine blood concentrations are affected by many factors, most notably age ≤ 3 years; a combination of young age, stunting and CYP2B6 GG or GT genotype could potentially result in sub-therapeutic nevirapine concentrations. Dosing recommendations for children should be reviewed in the light of these findings.
BACKGROUND:Nevirapine is an important component of paediatric combination HIV therapy. Adequate drug exposure is necessary in order to achieve long-lasting viral suppression. OBJECTIVES: To study the influence of age, drug dose and formulation type, nutritional status and CYP2B6 516G>T polymorphism on blood concentrations of nevirapine in children treated with generic antiretroviral drugs. METHODS: A multicentre study was conducted at four sites in India. HIV-infectedchildren receiving generic nevirapine-based fixed-dose combinations were recruited. Trough and 2 h nevirapine plasma concentrations were determined by HPLC. Characterization of the CYP2B6 gene polymorphism was performed using direct sequencing. Clinical and nutritional status was recorded. Groups were compared using the Mann-Whitney U-test and multivariable logistic regression analysis was performed to identify factors contributing to low drug levels. RESULTS: Ninety-four children of median age 78 months were studied; 60% were undernourished or stunted. Stunted children had a significantly lower 2 h nevirapine concentration compared with non-stunted children (P < 0.05); there were no significant differences in trough concentrations between different nutritional groups. Nevirapine levels were significantly higher in children with TT compared with GG and GT CYP2B6 genotypes (P < 0.01). Children ≤ 3 years had a 3.2 (95% confidence interval 1.07-9.45) times higher risk of having sub-therapeutic nevirapine concentrations. CONCLUSIONS:Nevirapine blood concentrations are affected by many factors, most notably age ≤ 3 years; a combination of young age, stunting and CYP2B6 GG or GT genotype could potentially result in sub-therapeutic nevirapine concentrations. Dosing recommendations for children should be reviewed in the light of these findings.
Authors: Akihiko Saitoh; Elizabeth Sarles; Edmund Capparelli; Francesca Aweeka; Andrea Kovacs; Sandra K Burchett; Andrew Wiznia; Sharon Nachman; Terence Fenton; Stephen A Spector Journal: AIDS Date: 2007-10-18 Impact factor: 4.177
Authors: Louisa Pollock; Laura Else; Goenke Poerksen; Elizabeth Molyneux; Peter Moons; Sarah Walker; William Fraser; David Back; Saye Khoo Journal: J Antimicrob Chemother Date: 2009-10-06 Impact factor: 5.790
Authors: C Padmapriyadarsini; N Pooranagangadevi; K Chandrasekaran; Sudha Subramanyan; C Thiruvalluvan; P K Bhavani; Soumya Swaminathan Journal: Int J Pediatr Date: 2009-07-02
Authors: Taimour Langaee; Mohammad H Al-Shaer; Yan Gong; Elizabeth Lima; Sampson Antwi; Anthony Enimil; Albert Dompreh; Hongmei Yang; Wael A Alghamdi; Lubbe Wiesner; Charles A Peloquin; Awewura Kwara Journal: Infect Genet Evol Date: 2021-04-08 Impact factor: 3.342
Authors: Sanjiv M Baxi; Ruth M Greenblatt; Peter Bacchetti; Chengshi Jin; Audrey L French; Marla J Keller; Michael H Augenbraun; Stephen J Gange; Chenglong Liu; Wendy J Mack; Monica Gandhi Journal: PLoS One Date: 2015-06-08 Impact factor: 3.240